多系统萎缩的诊断进展

doi:10.3969/j.issn.1003-9198.2025.02.003

Abstract

Abstract: Multiple system atrophy(MSA) is a rapidly progressive neurodegenerative disease characterized by a variety of clinical symptoms such as Parkinson's disease-like symptom clusters, cerebellar ataxia and autonomic dysfunction. At present, the biomarkers used in clinical diagnosis of MSA lack specificity, which makes early diagnosis difficult and easy to misdiagnose. MRI and cerebro spinal fluid(CSF) examination can assist in the diagnosis of MSA, but they are costly and have low specificity. It will take some time for the latest early detection technology of MSA, α-synuclein positron emission computed tomography (PET) imaging, to be applied in clinical practice. Blood and urine α-synuclein testing has the potential to be used in clinical diagnosis. Neurofilament light chain (NfL) and glial fibrillary acidic protein(GFAP) can also be used as biomarkers for the diagnosis of MSA, but further research is needed. The development of precise molecular biomarkers for the diagnosis of MSA is crucial, as it can revolutionize the diagnosis and treatment of MSA, and will facilitate early intervention and improve prognosis of the disease.

Key words: multiple system atrophy, diagnosis, parkinson's disease, α-synuclein

CLC Number:

R 741

LI Lin, LIU Anru, WAN Lijun, LIU Xuewu. Advances in the diagnosis of multiple system atrophy[J]. Practical Geriatrics, 2025, 39(2): 116-120.

References

[1] FANCIULLI A, WENNING G K. Multiple-system atrophy[J]. N Engl J Med, 2015,372(14): 1375-1376.
[2] HANNA AL-SHAIKH R, WERNICK A I, STRONGOSKY A J, et al. Spinocerebellar ataxia type 6 family with phenotypic overlap with multiple system atrophy[J]. Neurol Neurochir Pol, 2020, 54(4): 350-355.
[3] KÜHNEL L, RAKET L L, ÅSTRÖM D O, et al. Disease progression in multiple system atrophy-novel modeling framework and predictive factors[J]. Mov Disord, 2022, 37(8): 1719-1727.
[4] WENNING G K, STANKOVIC I, VIGNATELLI L, et al. The movement disorder society criteria for the diagnosis of multiple system atrophy[J]. Mov Disord, 2022, 37(6): 1131-1148.
[5] KOGA S, DICKSON D W. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy[J]. J Neurol Neurosurg Psychiatry, 2018, 89(2): 175-184.
[6] KOGA S, AOKI N, UITTI R J, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients[J]. Neurology, 2015, 85(5): 404-412.
[7] KOGA S, SEKIYA H, KONDRU N, et al. Neuropathology and molecular diagnosis of synucleinopathies[J]. Mol Neurodegener, 2021, 16(1): 83.
[8] DUTTA S, HORNUNG S, KRUAYATIDEE A, et al. α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy[J]. Acta Neuropathol, 2021, 142(3): 495-511.
[9] KOGA S, DICKSON D W. “Minimal change” multiple system atrophy with limbic-predominant α-synuclein pathology[J]. Acta Neuropathol, 2019, 137(1): 167-169.
[10] JAIN R S, KUMAR S, TEJWANI S. Medullary hot-cross bun sign in multiple system atrophy-cerebellar[J]. J Med Imaging Radiat Sci, 2016, 47(1): 113-115.
[11] RULSEHA M, KELLER J, RUSZ J, et al. Diffusion tensor imaging in the characterization of multiple system atrophy[J]. Neuropsychiatr Dis Treat, 2016, 12: 2181-2187.
[12] JELLINGER K. Evaluation of multiple system atrophy subtypes with FDG-PET[J]. Ann Indian Acad Neurol, 2021, 24(4): 468.
[13] ZHAO P, ZHANG B, GAO S, et al. Clinical features, MRI, and 18F-FDG-PET in differential diagnosis of Parkinson disease from multiple system atrophy[J]. Brain Behav, 2020, 10(11): e01827.
[14] KING A E, MINTZ J, ROYALL D R. Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders[J]. Mov Disord, 2011,26(7): 1218-1224.
[15] ROSHANBIN S, XIONG M, HULTQVIST G, et al. In vivo imaging of alpha-synuclein with antibody-based PET[J]. Neuropharmacology, 2022, 208: 108985.
[16] VERGNET S, HIVES F, FOUBERT-SAMIER A, et al. Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type[J]. Parkinsonism Relat Disord, 2019, 63: 199-203.
[17] WALLERT E D, VANDE GIESSEN E, KNOL R J J, et al. Imaging dopaminergic neurotransmission in neurodegenerative disorders[J]. J Nucl Med, 2022, 63(Suppl1): 27S-32S.
[18] OTANI R T V, YAMAMOTO J Y S, NUNES D M, et al. Magnetic resonance and dopamine transporter imaging for the diagnosis of parkinson's disease: a narrative review[J]. Arq Neuropsiquiatr, 2022, 80(5Suppl 1): 116-125.
[19] SCHWEIGHAUSER M, SHI Y, TARUTANI A, et al. Structures of α-synuclein filaments from multiple system atrophy[J]. Nature, 2020, 585: 464-469.
[20] KIELY A P, ASI Y T, KARA E, et al. α-synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?[J]. Acta Neuropathol, 2013, 125(5): 753-769.
[21] STROHÄKER T, JUNG B C, LIOU S H, et al. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts[J]. Nat Commun, 2019, 10: 5535.
[22] MARTINEZ-VALBUENA I, VISANJI N P, KIM A, et al. Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy[J]. Transl Neurodegener, 2022,11(1): 7.
[23] KURAPOVA R, CHOULIARAS L, O'BRIENJ T. The promise of amplification assays for accurate early detection of α-synucleinopathies: a review[J]. Exp Gerontol, 2022, 165: 111842.
[24] LAURENS B, CONSTANTINESCU R, FREEMAN R, et al. Fluid biomarkers in multiple system atrophy: a review of the MSA biomarker initiative[J]. Neurobiol Dis, 2015, 80: 29-41.
[25] DUTTA S, HORNUNG S, TAHA H B, et al. Development of a novel electrochemiluminescence ELISA for quantification of α-synuclein phosphorylated at Ser¹²⁹ in biological samples[J]. ACS Chem Neurosci, 2023, 14(7): 1238-1248.
[26] LINCOLN S J, ROSS O A, MILKOVIC N M, et al. Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy[J]. Parkinsonism Relat Disord, 2007, 13(6): 340-342.
[27] PENG C, GATHAGAN R J, LEE V M. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies[J]. Neurobiol Dis, 2018, 109(Pt B): 209-218.
[28] ZHANG L, CAO B, HOU Y, et al. Neurofilament light chain predicts disease severity and progression in multiple system atrophy[J]. Mov Disord, 2022, 37(2): 421-426.
[29] BARGAR C, DE LUCA C M G, DEVIGILI G, et al. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories[J]. Mol Neurodegener, 2021, 16(1): 82.
[30] OLSZEWSKA D A, MARTINEZ-VALBUENA I, VISANJI N, et al. A rapid, ultra-sensitive, RT-QuIC assay, with novel protocol, for MSA and PD using a single site skin biopsy and serum neurofilament light chain.(P1-1.Virtual)[J]. Neurology, 2022, 98(18_supplement):116.
[31] WANG Z, BECKER K, DONADIO V, et al. Skin α-synucleinaggregation seeding activity as a novel biomarker for parkinson disease[J]. JAMA Neurol,2020, 78(1): 1-11.
[32] MANNE S, KONDRU N, JIN H, et al. α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients[J]. Mov Disord, 2020, 35(2): 268-278.
[33] HEGMANS J P J J, GERBER P J, LAMBRECHT B N. Exosomes[J]. Methods Mol Biol, 2008, 484: 97-109.
[34] GOOLLA M, CHESHIRE W P, ROSS O A,et al. Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers[J]. Front Neurol, 2023, 14: 1210220.

Advances in the diagnosis of multiple system atrophy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 12

Metrics

Recommended 10

[1]	SUN Gaohui, FENG Meijiang. Advance in the diagnosis and treatment of Parkinson's disease [J]. Practical Geriatrics, 2025, 39(2): 110-115.
[2]	XIN Mengfan, FENG Meijiang. Advance in the diagnosis and treatment of Alzheimer's disease [J]. Practical Geriatrics, 2025, 39(2): 121-126.
[3]	WANG Jie, DU Ailian. Advances in the diagnosis and treatment of amyotrophic lateral sclerosis [J]. Practical Geriatrics, 2025, 39(2): 127-133.
[4]	BAO Lei, SUN Caizhi, ZHU Chenchen, QIN Haidong. Diagnostic value of serum MPO combined with hs-TNT in elderly patients with acute myocardial infarction [J]. Practical Geriatrics, 2025, 39(2): 144-147.
[5]	XUE Bingyan, XU Ruitong, GU Danyang, ZHU Guoqin. Correlation analysis of clinicopathologic features and prognosis in eighty-one elderly patients with pancreatic neuroendocrine tumors [J]. Practical Geriatrics, 2024, 38(7): 718-721.
[6]	WANG Nian-ci, XU You, LIU Xu, LIU Ying, LIU Han. Analysis of clinical features of sepsis-associated hemophagocytic lymphohistiocytosis in the elderly [J]. Practical Geriatrics, 2023, 37(3): 278-281.
[7]	JIANG Wen-yu, JIAO Chun-hua, TANG Na-na, ZHANG Hong-jie, MA Jing-jing. Efficacy and safety of double-balloon enteroscopy in the diagnosis and treatment of small intestinal diseases in elderly patients [J]. Practical Geriatrics, 2022, 36(9): 878-882.
[8]	ZHANG Xuan, QIAN Yuan-yuan, CHEN Xiao-chen, GUO Chun-yan. Value of serum advanced glycation end products (AGEs) and soluble receptor for AGEs in differential diagnosis of idiopathic pulmonary fibrosis and fibrotic parenchymal lung disease [J]. Practical Geriatrics, 2022, 36(6): 570-574.
[9]	LIU Jun-rong, SHI Jun-song, LI Lin. Effect of chest pain center on diagnosis and treatment process and short-term prognosis in elderly patients with acute non-ST-segment elevation myocardial infarction [J]. Practical Geriatrics, 2022, 36(4): 360-363.
[10]	WAN Cheng, CHEN Bai-bing, SHEN Jian-xin, CHEN Zhi-qiang. A diagnostic method of high myopia based on artificial intelligence ResNeXt [J]. Practical Geriatrics, 2022, 36(3): 280-283.
[11]	LIU Yi, YIN Shao-jun, KONG Zhi-bin, ZHU Zhen, LI Hong, SONG Shuang, SONG Yi-yi. Clinical characteristics of elderly patients with acute pulmonary thromboembolism presenting with low Wells score [J]. Practical Geriatrics, 2021, 35(9): 923-926.
[12]	XU Lan, ZHU Feng, ZHANG Dian-fu. Application of diagnosis-related groups in improving disease management in department of geriatrics [J]. Practical Geriatrics, 2021, 35(5): 537-540.